The impact of plasma epstein–barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study-Reference-Cited by-同舟云学术

The impact of plasma epstein–barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study

Published:2014-07-22 Issue:6 Volume:111 Page:1102-1111
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Tang L-Q,Chen Q-Y,Guo S-S,Chen W-H,Li C-F,Zhang L,Lai X-P,He Y,Xu Y-X-X,Hu D-P,Wen S-H,Peng Y-T,Liu H,Liu L-T,Yan S-M,Guo L,Zhao C,Cao K-J,Liu Q,Qian C-N,Ma J,Guo X,Zeng M-S,Mai H-Q

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014393.pdf

Reference43 articles.

1. An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH (2011) Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 117 (16): 3750–3757.

2. Calvaruso V, Maimone S, Gatt A, Tuddenham E, Thursz M, Pinzani M, Burroughs AK (2008) Coagulation and fibrosis in chronic liver disease. Gut 57 (12): 1722–1727.

3. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ (2002) Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94 (21): 1614–1619.

4. Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B (2004) Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 22 (15): 3053–3060.

5. Chan KC, Hung EC, Woo JK, Chan PK, Leung SF, Lai FP, Cheng AS, Yeung SW, Chan YW, Tsui TK, Kwok JS, King AD, Chan AT, van Hasselt AC, Lo YM (2013) Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 119 (10): 1838–1844.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Prognostic Model Predicts Outcomes in Non-Metastatic Nasopharyngeal Carcinoma Based on Inflammation, Nutrition, and Coagulation Signature;Journal of Inflammation Research;2023-11

2. Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome expression could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 monotherapy;2023-06-13

3. Early biomolecular changes in brain microvascular endothelial cells under Epstein–Barr virus influence: a Raman microspectroscopic investigation;Integrative Biology;2022-07-03

4. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial;Journal of Clinical Oncology;2022-04-10

5. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti–Programmed Cell Death 1 Immunotherapy;JAMA Network Open;2022-03-01